Abstract
Drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease include acetylcholinesterase inhibitor (i.e., tacrine, donepezil, rivastigmine, and galantamine) and glutamate-modulating (i.e., memantine) drugs. Because these drugs have modest benefits, various alternative drug therapies have been of interest. Drugs with vasodilator activity were originally tried in dementia when it was hypothesized that the condition was due to cerebrovascular insufficiency. Isoxsuprine and ergoloid mesylates are FDA approved for the treatment of dementia, although they have limited evidence of benefit and are rarely used. The hypothesis that free radicals may initiate and maintain mechanisms responsible for neurodegeneration in dementia has stimulated interest in investigating various antioxidant and anti-inflammatory drugs. There is no evidence that other drug therapies, including vitamin E, selegiline, nonsteroidal anti-inflammatory drugs, statin drugs, omega-3 fatty acids, estrogen or combined estrogen plus progestin therapy, or B vitamins, are sufficiently effective and safe to justify their clinical use for the treatment of dementing disorders.
- Birks J., Flicker L. (2003). Selegiline for Alzheimer’s disease (Article No. CD000442). Cochrane Database of Systematic Reviews, Issue 1. doi:
10.1002/14651858.CD000442 Crossref, Google Scholar - Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Scheltens P. (2010). Revising the definition of Alzheimer’s disease: A new lexicon. Lancet, 9, 1118–1127.
10.1016/S1474-4422(10)70223-4 Crossref, Google Scholar - Elliott C.G., Brown A.L., Smith T.C. (1973). Multi-centre general practitioner trial of isoxsuprine in cerebrovascular disease: A pilot study. Current Medical Research and Opinion, 1, 554–562.
10.1185/03007997309111721 Crossref Medline, Google Scholar - Hollister L.E., Yesavage J. (1984). Ergoloid mesylates for senile dementias: Unanswered questions. Annals of Internal Medicine, 100, 894–898. Crossref Medline, Google Scholar
- Howland R.H. (2006a). MAOI antidepressant drugs. Journal of Psychosocial Nursing and Mental Health Services, 44(6), 9–12. Link, Google Scholar
- Howland R.H. (2006b). Transdermal selegiline: A novel MAOI formulation for depression. Journal of Psychosocial Nursing and Mental Health Services, 44(7), 9–12. Link, Google Scholar
- Howland R.H. (2010). Drug therapies for cognitive impairment and dementia. Journal of Psychosocial Nursing and Mental Health Services, 48(4), 11–14.
10.3928/02793695-20100311-01 Link, Google Scholar - Hussain S.M., Gedye J.L., Naylor R., Brown A.L. (1976). The objective measurement of mental performance in cerebrovascular disease. The Practitioner, 216, 222–228. Medline, Google Scholar
- Launer L.J. (2003). Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer’s disease: Dissecting the epidemiological evidence. Drugs, 63, 731–739.
10.2165/00003495-200363080-00001 Crossref Medline, Google Scholar - McGuinness B., Craig D., Bullock R., Passmore P. (2009). Statins for the prevention of dementia (Article No. CD003160). Cochrane Database of Systematic Reviews, Issue 2. doi:
10.1002/14651858.CD003160.pub2 Crossref, Google Scholar - O’Brien J.T., Burns A. (2010). Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology. Advance online publication. doi:
10.1177/0269881110387547 Crossref Medline, Google Scholar - Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Thal L.J. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine, 352, 2379–2388.
10.1056/NEJMoa050151 Crossref Medline, Google Scholar - Praticò D., Delantry N. (2000). Oxidative injury in diseases of the central nervous system: Focus on Alzheimer’s disease. American Journal of Medicine, 109, 577–585.
10.1016/S0002-9343(00)00547-7 Crossref Medline, Google Scholar - Quinn J.F., Raman R., Thomas R.G., Yurko-Mauro K., Nelson E.B., Van Dyck C., Aisen P.S. (2010). Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. Journal of the American Medical Association, 304, 1903–1911.
10.1001/jama.2010.1510 Crossref, Google Scholar - Rabins P.V., Blacker D., Rovner B.W., Rummans T., Schneider L.S., Tariot P.N., Fochtmann L.J. (2007). American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. American Journal of Psychiatry, 164(12 Suppl.), 5–56. Medline, Google Scholar
- Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., Oremus M. (2008). Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Annals of Internal Medicine, 148, 379–397. Crossref Medline, Google Scholar
- Rouy J.M., Douillon A.M., Compan B., Wolmark Y. (1989). Ergoloid mesylates (“Hydergine”) in the treatment of mental deterioration in the elderly: A 6-month double-blind, placebo-controlled trial. Current Medical Research and Opinion, 11, 380–389.
10.1185/03007998909110139 Crossref Medline, Google Scholar - Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Thal L.J. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. New England Journal of Medicine, 336, 1216–1222.
10.1056/NEJM199704243361704 Crossref Medline, Google Scholar - Thienhaus O.J., Wheeler B.G., Simon S., Zemlan F.P., Hartford JT. (1987). A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine®) in mild dementia. Journal of the American Geriatrics Society, 35, 219–223. Crossref Medline, Google Scholar
- Thompson T.L., Filley C.M., Mitchell W.D., Culig K.M., LoVerde M., Byyny R.L. (1990). Lack of efficacy of hydergine in patients with Alzheimer’s disease. New England Journal of Medicine, 323, 445–448.
10.1056/NEJM199008163230704 Crossref Medline, Google Scholar - van Loveren-Huyben C.M., Engelaar H.F., Hermans M.B., van der Bom J.A., Leering C., Munnichs J.M. (1984). Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine®) in subjects with senile mental deterioration. Journal of the American Geriatrics Society, 32, 584–589. Crossref Medline, Google Scholar
